全球产前和新生儿基因检测市场规模（按检测类型、应用、地区、范围和预测）

产前及新生儿基因检测市场规模及预测

2024 年产前和新生儿基因检测市场规模价值 60.2 亿美元，预计到 2030 年将达到 151.3 亿美元，预测期内（2026-2032 年）的复合年增长率为 13.46%。

推动全球产前和新生儿基因检测市场的因素

技术发展：聚合酵素链锁反应(PCR)、次世代定序(NGS) 和微阵列分析等基因检测技术的进步使得检测更加准确和彻底。

遗传病患病率不断上升：婴儿和胎儿中遗传疾病和染色体异常的发生率不断上升，推动了对基因检测的需求，以便早期诊断疾病并及时治疗。

接受度和认知度不断提升：推动市场扩张的因素之一是家长和医疗专业人士对产前和新生儿筛检基因检测益处的认识不断提高。随着人们对早期检测和早期疗育价值的认识不断提高，基因检测正变得越来越被广泛接受。

政府支持和措施：支持性法律法规加上政府推动新生儿筛检计画和提供产前基因检测机会的宣传活动正在帮助市场扩大。

母亲年龄增长：高龄产妇的新生儿较容易出现染色体异常。许多女性为了确定自身基因异常的风险而延迟生育，这增加了产前筛检和检测服务的需求。

技术可负担性和可近性：随着基因检测技术越来越广泛地被消费者和医疗保健提供者所使用，其可负担性和可近性也不断提高，有助于推动市场扩张。

需求：非侵入性检测技术 随着消费者青睐无细胞胎儿 DNA 检测等非侵入性产前检测 (NIPT) 技术，市场正在扩大。

个人化医疗的快速发展：个人化医疗运动推动了产前和婴儿护理中基因检测的使用，该运动强调根据个人基因组成进行有针对性的干预。

技术融合与整合：将基因检测与其他医学诊断技术相结合，将使产前和新生儿筛检计划更加有效和高效，有助于扩大市场。

增加医疗保健支出：透过使更多人能够享受基因检测服务，一般医疗保健支出的增加和保险公司对这些服务的覆盖范围的扩大都将支持行业增长。

限制全球产前和新生儿基因检测市场的因素

法规合规性：由于严格的法规和核准程序，新的测试技术和工艺可能难以采用。为了将产品推向市场，公司必须应对复杂的法规环境。

伦理问题：隐私、知情同意以及基于基因资讯的歧视可能性是基因检测引发的伦理问题之一。有些人可能不愿意接受检测，因为他们担心自己的基因资讯会被雇主、保险公司和其他机构取得。

成本：一些个人和医疗保健系统可能会发现基因检测的费用过高，尤其是在资源匮乏和保障不足的地区。高昂的价格可能会阻碍市场扩张，并限制检测的可及性。

认知度和教育程度低：许多患者和医疗保健专业人员可能并未充分了解基因检测的益处和局限性，这可能导致现有检测的普及率较低。需要进行宣传活动，提高人们对产前和新生儿基因检测的认知和理解。

技术限制：儘管基因检测取得了进展，但其特异性、敏感性和准确性仍然有限，尤其是在识别罕见遗传疾病和突变方面。我们需要技术进步，使基因检测更具临床实用性和可靠性。

解读困难：确定基因检测观察的含义可能很困难，需要专门训练。缺乏遗传学专业知识可能会使医疗专业人员难以为患者及其家属提供适当的咨询，并难以解读检测结果。

文化与社会因素：人们对基因检测的决定可能受到其文化观点、社会态度和宗教观念的影响。此外，与遗传疾病相关的文化禁忌和耻辱感也可能影响人们对基因检测的接受程度。

资料安全和隐私：人们可能出于对资料安全和隐私侵犯的担忧，不愿接受基因检测。患者不仅担心自身基因资讯的保密性，还担心其被滥用或非法取得。

目录

第一章 引言

• 市场定义
• 市场区隔
• 调查方法

第二章执行摘要

• 主要发现
• 市场概览
• 市集亮点

第三章市场概述

• 市场规模和成长潜力
• 市场趋势
• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析

4. 产前和新生儿基因检测市场（按检测类型）

• 携带者筛检
• 非侵入性产前检测（NIPT）
• 染色体微阵列分析（CMA）
• 生化基因检测

5. 产前和新生儿基因检测市场（按应用）

• 唐氏症筛检
• 囊肿纤维化筛检
• 脊髓性肌肉萎缩症（SMA）筛检

第六章区域分析

• 北美洲
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 英国
• 德国
• 法国
• 义大利
• 亚太地区
• 中国
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中东和非洲
• 南非
• 沙乌地阿拉伯
• 阿拉伯聯合大公国

第七章市场动态

• 市场驱动因素
• 市场限制
• 市场机会
• COVID-19 市场影响

第八章 竞争态势

• 主要企业
• 市场占有率分析

第九章 公司简介

• Abbott Laboratories
• Illumina Inc.
• F. Hoffmann-La Roche AG（Roche Diagnostics）
• Natera
• Quest Diagnostics
• Laboratory Corporation of America（LabCorp）
• Thermo Fisher Scientific
• Bio-Rad Laboratories

第十章 市场展望与机会

• 新兴技术
• 未来市场趋势
• 投资机会

第十一章 附录

• 简称列表
• 来源和参考文献

Prenatal And Newborn Genetic Testing Market Size And Forecast

Prenatal And Newborn Genetic Testing Market size was valued at 6.02 USD Billion in 2024 and is projected to reach 15.13 USD Billion by 2030, growing at a CAGR of 13.46% during the forecast period 2026-2032.

Global Prenatal And Newborn Genetic Testing Market Drivers

The market drivers for the Prenatal And Newborn Genetic Testing Market can be influenced by various factors. These may include:

Technological Developments: More precise and thorough testing is made possible by the ongoing developments in genetic testing technologies, including polymerase chain reaction (PCR), next-generation sequencing (NGS), and microarray analysis.

Growing Prevalence of Genetic Disorders: In order to diagnose illnesses early and enable prompt therapies, there is an increasing need for genetic testing due to the increased frequency of genetic disorders and chromosomal abnormalities among infants and foetuses.

Growing Acceptance and Awareness: One factor driving market expansion is the growing knowledge among parents and medical professionals of the advantages of genetic testing for prenatal and neonatal screening. Genetic testing is becoming more widely accepted as awareness of the value of early detection and intervention grows.

Government Support and Initiatives: Supportive laws and regulations, in conjunction with government campaigns to advance newborn screening programmes and provide access to prenatal genetic testing, are what propel the market's expansion.

Growing Maternal Age: Newborns that have older mothers are more likely to have chromosomal abnormalities. Prenatal screening and testing services are in greater demand as many women put off having children in order to determine their risk of genetic abnormalities.

Technological Affordability and Accessibility: As genetic testing technologies become more widely available to consumers and healthcare providers, their affordability and accessibility are growing, propelling market expansion.

Wanted: Non-Invasive Testing Techniques The market is growing because consumers prefer non-invasive prenatal testing (NIPT) techniques such cell-free foetal DNA testing because they are less risky and have higher accuracy than invasive procedures like amniocentesis and chorionic villus sampling (CVS).

Rapid Growth in Personalised Medicine: The use of genetic testing in prenatal and infant care is being driven by the trend towards personalised medicine, which emphasises targeted interventions based on individual genetic makeup.

Technological Convergence and Integration: By combining genetic testing with other medical diagnostic techniques and technologies, prenatal and neonatal screening programmes may be made more effective and efficient, which will propel the market's expansion.

Growing Healthcare Expenditure: By making genetic testing services more widely available to a greater audience, the general increase in healthcare spending along with the insurance companies' growing coverage of these services both support the growth of the industry.

Global Prenatal And Newborn Genetic Testing Market Restraints

Several factors can act as restraints or challenges for the Prenatal And Newborn Genetic Testing Market . These may include:

Regulatory Compliance: New testing techniques and technologies may find it difficult to gain traction due to onerous regulatory regulations and approval procedures. To get their products to market, businesses have to traverse complicated regulatory environments, which can be expensive and time-consuming.

Ethical Concerns: Privacy, informed consent, and the possibility of discrimination based on genetic information are among the ethical issues that genetic testing brings up. Some people might be reluctant to get tested because they are concerned about the potential uses of their genetic information by employers, insurance companies, or other organisations.

Cost: Some people or healthcare systems may find the expense of genetic testing to be prohibitive, especially in areas with little resources or insufficient insurance coverage. Expensive prices could prevent market expansion and restrict access to testing.

Low Awareness and Education: There may be a low use of the available tests since many patients and healthcare professionals may not completely comprehend the advantages and restrictions of genetic testing. Campaigns to raise awareness and improve comprehension of prenatal and neonatal genetic testing are required.

Technological Restrictions: Despite advancements in genetic testing, specificity, sensitivity, and accuracy are still limited, especially when it comes to identifying uncommon genetic illnesses or variations. For genetic tests to be more clinically useful and reliable, technological advancements are required.

Interpretation Difficulties: Determining the meaning of genetic test findings can be difficult and need specific training. Lack of genetics expertise may make it difficult for medical professionals to appropriately counsel patients and their families and interpret test results.

Cultural and Societal Factors: People's decisions on genetic testing may be influenced by their cultural views, societal attitudes, and religious perspectives. Testing uptake may be impacted by cultural taboos or stigmas in some cultures related to genetic diseases.

Data Security and Privacy: People may be discouraged from having genetic testing done due to worries about data security and privacy violations. Patients might be concerned about misuse or illegal access to their genetic information, as well as its confidentiality.

Global Prenatal And Newborn Genetic Testing Market Segmentation Analysis

The Global Prenatal And Newborn Genetic Testing Market is Segmented on the basis of Test Type, Application, And Geography.

Prenatal And Newborn Genetic Testing Market, By Test Type

• Carrier Screening: This type of test identifies individuals who carry a gene mutation for a genetic disorder. Carrier screening can be done before pregnancy, during pregnancy, or after a baby is born.
• Non-Invasive Prenatal Testing (NIPT): NIPT is a blood test that can screen for certain chromosomal abnormalities in a fetus. NIPT is done during pregnancy, usually between 10 and 14 weeks.
• Chromosomal Microarray Analysis (CMA): CMA is a test that can detect small deletions or duplications of chromosomes. CMA can be used to diagnose a variety of genetic disorders, including intellectual disability, developmental delays, and birth defects.
• Biochemical Genetic Testing: Biochemical genetic testing measures the levels of enzymes or other chemicals in the blood or other tissues. Biochemical genetic testing can be used to diagnose a variety of genetic disorders, including metabolic disorders.

Prenatal And Newborn Genetic Testing Market, By Application

• Down Syndrome Screening: Down syndrome is a genetic disorder that causes developmental delays and intellectual disabilities. Down syndrome screening is a group of tests that can help to identify a pregnancy at increased risk of having a baby with Down syndrome.
• Cystic Fibrosis Screening: Cystic fibrosis is a genetic disorder that affects the lungs, pancreas, and other organs. Cystic fibrosis screening is a test that can identify babies who are carriers of the cystic fibrosis gene.
• Spinal Muscular Atrophy (SMA) Screening: Spinal muscular atrophy (SMA) is a genetic disorder that affects the muscles. SMA sc

Prenatal And Newborn Genetic Testing Market, By Geography

• North America: Market conditions and demand in the United States, Canada, and Mexico.
• Europe: Analysis of the Prenatal And Newborn Genetic Testing Market in European countries.
• Asia-Pacific: Focusing on countries like China, India, Japan, South Korea, and others.
• Middle East and Africa: Examining market dynamics in the Middle East and African regions.
• Latin America: Covering market trends and developments in countries across Latin America.

Key Players

• The major players in the Prenatal And Newborn Genetic Testing Market are:
• Abbott Laboratories
• Illumina Inc.
• F. Hoffmann-La Roche AG
• Natera
• Quest Diagnostics
• Laboratory Corporation of America
• Thermo Fisher Scientific
• Bio-Rad Laboratories

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Prenatal And Newborn Genetic Testing Market, By Test Type

• Carrier Screening
• Non-invasive Prenatal Testing (NIPT)
• Chromosomal Microarray Analysis (CMA)
• Biochemical Genetic Testing

5. Prenatal And Newborn Genetic Testing Market, By Application

• Down Syndrome Screening
• Cystic Fibrosis Screening
• Spinal Muscular Atrophy (SMA) Screening

6. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

7. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

8. Competitive Landscape

• Key Players
• Market Share Analysis

9. Company Profiles

• Abbott Laboratories
• Illumina Inc.
• F. Hoffmann-La Roche AG (Roche Diagnostics)
• Natera
• Quest Diagnostics
• Laboratory Corporation of America (LabCorp)
• Thermo Fisher Scientific
• Bio-Rad Laboratories

10. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

11. Appendix

• List of Abbreviations
• Sources and References